HCA's Uninsured Patient Problem Will Define Tomorrow's Call

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

HCA typically reports earnings before the market opens, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

HCA's post-earnings price behavior shows significant volatility, with an average absolute Day 0 move of 5.08% and Day 0 range of 5.90%. The most recent earnings on April 24, 2026 triggered the largest reaction in the dataset—a sharp -8.77% decline—following the company's first earnings miss in over a year. Prior to that, January 2026 saw a +7.08% pop on a strong beat.

The historical pattern reveals that initial reactions can be dramatic in either direction, but Day +1 follow-through tends to be more muted, averaging 2.85% with a 3.52% range. Notably, several quarters show reversal patterns where Day 0 losses are partially recovered on Day +1 (April 2026, January 2025) or Day 0 gains extend further (October 2025, January 2025).

Given the 8.53% expected move priced into options for the upcoming August expiration, the market is anticipating volatility roughly in line with HCA's historical average, though notably higher than the more subdued moves seen in mid-2025. Investors should prepare for a potentially significant Day 0 reaction, particularly if results or guidance deviate materially from the tight consensus range.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.53% expected move through the August 21 expiration, which aligns closely with HCA's average historical Day 0 move of 5.08% plus typical Day +1 follow-through of 2.85%. This suggests options traders are anticipating volatility consistent with the stock's established post-earnings behavior, with no unusual premium for heightened uncertainty despite the geopolitical backdrop.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on HCA, with a consensus rating of 4.00 (Buy) and an average price target of $467.73, implying 24.2% upside from the current price of $376.50. The Street's outlook is supported by 13 Strong Buy ratings and 1 Moderate Buy, though 10 Hold ratings and 1 Strong Sell suggest some caution.

The sentiment trend has deteriorated over the past month, with the average recommendation slipping from 4.08 to 4.00 as one analyst downgraded from Strong Buy to Hold. This modest erosion in conviction comes as the stock has declined roughly 18% from its highs, trading well below most moving averages and reflecting concerns about margin pressure and the sustainability of volume growth.

Price target dispersion is wide, ranging from a low of $369.00 to a high of $635.00, indicating significant disagreement about HCA's fair value. The mean target of $467.73 sits roughly in the middle of this range, suggesting the average analyst sees the recent selloff as overdone and expects a meaningful recovery if the company can demonstrate that Q1's miss was an aberration rather than the start of a negative trend.

Part 4: Technical Picture

HCA enters earnings in a technically compromised position, with the Barchart Technical Opinion registering an 80% Sell signal, though this represents an improvement from the 96% Sell reading one week ago and compares to 72% Sell one month ago. The stock is trading at $376.50, below its 10-day ($378.86), 20-day ($390.65), 50-day ($389.94), 100-day ($437.24), and 200-day ($458.02) moving averages, though it has managed to climb above the 5-day average ($372.61), suggesting a potential near-term stabilization.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum remains negative, though less extreme than medium and longer timeframes
• Medium-term (100% Sell): Strong sell signal reflects significant weakness in the intermediate trend as the stock trades well below key moving averages
• Long-term (100% Sell): Strong sell signal confirms the longer-term downtrend remains intact, with price more than 17% below the 200-day moving average

Trend Characteristics: The signal strength is classified as Strong but with a Weakening direction, suggesting selling pressure may be beginning to exhaust even as the overall trend remains negative.

The 100-day and 200-day moving averages at $437.24 and $458.02 represent significant overhead resistance levels that would need to be reclaimed to signal a meaningful trend reversal. More immediately, the cluster of shorter-term averages between $378 and $391 creates a resistance zone the stock must clear to confirm the recent bounce off $372 has legs. The technical setup is cautionary heading into earnings—while the worst of the selling pressure may be abating, the stock lacks bullish momentum and remains vulnerable to further downside if results or guidance disappoint.

Key support sits at the recent low near $372 (5-day MA), while the 10-day average at $378.86 represents immediate resistance. A strong earnings beat could propel the stock toward the 20-day and 50-day averages near $390, but failure to impress would likely retest support and potentially trigger a breakdown to new lows. The overall technical setup is cautionary—the stock is oversold but not yet showing signs of a sustainable reversal, making earnings execution and forward guidance critical to determining whether this is a buying opportunity or a value trap.